The year concluded with a strong fourth quarter, highlighting a recovery in operational performance and validating the effectiveness of strategic initiatives implemented throughout the year. Full-year highlights include:

• Net sales increased by 6.1% to SEK 290.3 million, with 5.3% organic growth
• Q4 sales surged by 22.4%, driven by strong MedTech demand
• EBITDA for Q4 improved significantly to SEK 16.6 million. Adjusted EBITDA amounted to SEK 24.1 million
• Cash flow from operations was SEK 17.9 million for the full year
• Launch of patient-specific simulation with VIST® / Ankyras® integration
• Notable strategic orders from top 20 global MedTech companies
• Appointment of Frans Venker as new CEO, effective January 1, 2025

“These achievements reflect the trust our customers place in us and the consistent dedication of our team,” says Frans Venker, CEO of Mentice AB. “We enter 2025 focusing on building commercial strength, particularly in the U.S., while continuing to innovate across our simulation portfolio, with a clear focus on advancing patient outcomes through simulation technology.”

The Annual Report 2024 provides a comprehensive overview of Mentice’s operational and financial performance, market developments, strategic priorities, and sustainability initiatives. It is available to shareholders and interested parties at: https://investor.mentice.com/financial-report/2024. A printed copy can be requested in writing by contacting: stacy.hammar@mentice.com.